Alkem Laboratories Sees Sharp Open Interest Surge Amid Bearish Momentum

Open Interest and Volume Dynamics

On 28 Sep 2026, Alkem Laboratories (symbol: ALKEM) recorded an open interest (OI) of 24,338 contracts, up from 21,156 contracts previously, marking an increase of 3,182 contracts or 15.04%. This rise in OI is significant given the stock’s current trading context. The volume for the day stood at 12,673 contracts, indicating active participation in the derivatives market. The futures segment alone accounted for a value of approximately ₹36,013 lakhs, while options contributed a staggering ₹4,729 crores, culminating in a total derivatives value of ₹36,211 lakhs.

The underlying stock price closed at ₹5,206, hovering just 3.01% above its 52-week low of ₹5,051. Despite this proximity to a yearly low, the stock has underperformed its sector by 0.68% on the day and has declined by 3.88% over the past three consecutive sessions. This juxtaposition of rising open interest against falling prices often points to increased speculative activity or hedging strategies by market participants.

Market Positioning and Sentiment

The surge in open interest amid a declining price trend suggests that traders may be establishing fresh positions anticipating a directional move. However, the nature of these positions—whether predominantly bullish or bearish—requires deeper analysis of option chain data and put-call ratios, which currently indicate a mixed sentiment.

Adding to the complexity, Alkem Laboratories is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—highlighting a sustained downtrend. Investor participation appears to be waning, as evidenced by a sharp 89.23% drop in delivery volume to 12,110 shares on 25 Sep compared to the five-day average. This decline in delivery volume suggests reduced conviction among long-term investors, potentially leaving room for short-term traders to influence price movements through derivatives.

Valuation and Market Capitalisation Context

Alkem Laboratories is classified as a mid-cap pharmaceutical and biotechnology company with a market capitalisation of ₹62,395 crores. The company’s Mojo Score currently stands at 44.0, reflecting a Sell rating, a downgrade from its previous Hold grade on 24 Sep 2026. This downgrade aligns with the recent price weakness and deteriorating technical indicators.

Implications of Rising Open Interest in a Bearish Phase

Typically, an increase in open interest during a falling price trend can indicate that new short positions are being added, signalling bearish sentiment. Alternatively, it may also reflect hedging activity by institutional investors or arbitrageurs seeking to protect existing long positions. The sizeable open interest in options, valued at over ₹4,729 crores, suggests that market participants are actively using options strategies to express views or manage risk.

Given the stock’s liquidity profile, with a 5-day average traded value sufficient to support trades up to ₹1.25 crores, the derivatives market for Alkem Laboratories remains accessible for both retail and institutional players. However, the sharp fall in delivery volumes points to a lack of strong buying interest at the cash level, which could limit sustained upward momentum despite the derivatives activity.

Technical and Fundamental Outlook

From a technical standpoint, the stock’s position below all major moving averages and its proximity to the 52-week low indicate a bearish bias. The downgrade in Mojo Grade to Sell further reinforces this negative outlook. Investors should be cautious as the current open interest surge may precede increased volatility rather than a clear directional breakout.

Fundamentally, Alkem Laboratories operates in the Pharmaceuticals & Biotechnology sector, which is subject to regulatory risks, pricing pressures, and competitive dynamics. The mid-cap status implies moderate market capitalisation, which can lead to higher volatility compared to large-cap peers. The recent downgrade in Mojo Grade suggests that the company’s financial metrics or growth prospects may have deteriorated relative to sector peers.

Investor Takeaway

Investors should interpret the rising open interest in Alkem Laboratories’ derivatives with caution. While increased activity can signal upcoming price moves, the current technical and fundamental indicators suggest a bearish environment. The stock’s underperformance relative to its sector and the Sensex, combined with falling delivery volumes, points to weak investor conviction at the cash level.

For traders, the derivatives market offers opportunities to capitalise on volatility through options and futures strategies. However, given the Sell rating and recent downgrade in Mojo Grade, a conservative approach is advisable until clearer signs of trend reversal emerge. Monitoring open interest trends alongside price action and volume will be critical in assessing the sustainability of any directional bets.

Conclusion

Alkem Laboratories Ltd’s recent surge in open interest amidst a declining price trend highlights a nuanced market positioning scenario. The derivatives market activity suggests that participants are gearing up for potential volatility, but the overall bearish technical setup and deteriorating investor sentiment warrant prudence. Investors and traders alike should closely watch evolving volume and open interest patterns to gauge the stock’s next directional move.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →